<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375436</url>
  </required_header>
  <id_info>
    <org_study_id>NTRX-07-C101</org_study_id>
    <nct_id>NCT04375436</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of NTRX-07 in Healthy Volunteers</brief_title>
  <official_title>NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroTherapia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Integrium</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orange County Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NeuroTherapia, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, placebo-controlled, modified parallel-design single ascending dose (SAD) in adult&#xD;
      healthy volunteers (HVs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study NTRX-07-C101 will be conducted with a modified parallel design, incorporating sentinel&#xD;
      subjects and a staggered-dosing-days approach.&#xD;
&#xD;
      Up to 6 cohorts, A-F, are planned for a total of 48 completing subjects. Each dose cohort&#xD;
      will be randomized with 6 subjects receiving active drug and 2 placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study NTRX-07-C101 will be conducted with a modified parallel design, incorporating sentinel subjects and a staggered-dosing-days approach.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment emergent adverse events of NTRX-07</measure>
    <time_frame>Seven days</time_frame>
    <description>Reported Treatment related Adverse Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with Treatment related subjective effects of NTRX-07</measure>
    <time_frame>Seven days</time_frame>
    <description>Reported Treatment related subjective effects Events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma levels of NTRX-07</measure>
    <time_frame>24 hours</time_frame>
    <description>Plasma levels of NTRX-07</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pain, Neuropathic</condition>
  <arm_group>
    <arm_group_label>NTRX-07-SDD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>NTRX-07-SDD at 0.3-8mg/kg; single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NTRX-07-SDD</intervention_name>
    <description>NTRX-07-SDD for oral administration</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>NTRX-07-SDD</arm_group_label>
    <other_name>MDA7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • Written, informed consent.&#xD;
&#xD;
               -  Adult healthy male or females, ages 18-60 years, inclusive, who are surgically&#xD;
                  sterilized (including hysterectomy and/or bilateral oophorectomy but not tubal&#xD;
                  ligation) or naturally postmenopausal (2 without menses and documented blood&#xD;
                  follicle-stimulating hormone ≥40 MIU/mL).&#xD;
&#xD;
        years&#xD;
&#xD;
          -  Good health as determined by medical history, physical examination, vital signs, ECG,&#xD;
             and clinical laboratory measurements.&#xD;
&#xD;
          -  Clinical laboratories within normal limits at screening (including blood glucose).&#xD;
&#xD;
          -  Body mass index (BMI) of 18-35 kg/m 2 inclusive with body weight&#xD;
&#xD;
        &gt;50 kg.&#xD;
&#xD;
        • Able to comply with the study regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any acute or chronic illness.&#xD;
&#xD;
               -  Pregnant or lactating females.&#xD;
&#xD;
               -  Positive serology for human immunodeficiency virus (HIV), hepatitis B virus (HBV)&#xD;
                  (if not vaccinated) or hepatitis C virus (HCV).&#xD;
&#xD;
               -  Any known or suspected allergies to the study drug or its constituents.&#xD;
&#xD;
               -  Inadequate venous access to allow collection of blood samples.&#xD;
&#xD;
               -  History of drug or alcohol abuse, consumption of alcohol within 48 hours prior to&#xD;
                  treatment assignment, or a positive test for alcohol or drugs with a high&#xD;
                  potential for abuse prior to treatment assignment and readmission to the Clinical&#xD;
                  Research Unit (CRU).&#xD;
&#xD;
               -  Subjects with history of (within the previous 12 months) or current use of&#xD;
                  marijuana or positive urine drug screen for cannabinoids at screening or prior to&#xD;
                  the first dose.&#xD;
&#xD;
               -  History of seizures or current existing seizure disorder. High risk for seizure&#xD;
                  disorders due to underlying medical condition and/or head trauma.&#xD;
&#xD;
               -  Is a smoker of more than 10 cigarettes or 3 cigars or 3 pipes per day, and is&#xD;
                  unable to refrain from smoking while confined to the CRU.&#xD;
&#xD;
               -  Calculated creatinine clearance (using Cockroft and Gault formula) &lt;80 mL/min.&#xD;
&#xD;
               -  Resting 12-lead ECG showing QTcB interval &gt;450 msec or any other clinically&#xD;
                  significant abnormality in the opinion of the investigator/ sponsor.&#xD;
&#xD;
               -  Blood donation, participation in a multiple blood draws clinical study 30 days&#xD;
                  prior (&gt;120 mL)&#xD;
&#xD;
               -  Major trauma or surgery with or without blood loss within 90 days prior to&#xD;
                  treatment assignment.&#xD;
&#xD;
               -  Use of any experimental or investigational drugs within 30 days prior to&#xD;
                  treatment assignment.&#xD;
&#xD;
               -  Use of any prescription or nonprescription drugs, vitamins, or dietary&#xD;
                  supplements within 14 days prior to treatment assignment, or expected use during&#xD;
                  trial enrollment.&#xD;
&#xD;
               -  Any current condition, that in either the Investigator's or sponsor's opinion&#xD;
                  would represent an unacceptable safety risk while participating in this study or&#xD;
                  interfere with trial participation or evaluation of results.&#xD;
&#xD;
               -  Severe mental incapacity, unwillingness, language barrier, serious behavioral&#xD;
                  issues, evidence of substance abuse, or any other situation, which would preclude&#xD;
                  an understanding of, and adherence to study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Foss, MD</last_name>
    <role>Study Director</role>
    <affiliation>NeuroTherapia, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

